Meta-Analysis
Copyright ©The Author(s) 2020.
World J Cardiol. Nov 26, 2020; 12(11): 584-598
Published online Nov 26, 2020. doi: 10.4330/wjc.v12.i11.584
Table 1 Summary of baseline characteristics of included studies, n (%)
Study
n
ICI
Cancer type
Males
Median age (range), yr
Median follow-up (range), mo
Race, Asian
Race, Black
Tobacco users
Antonia et al[8], 2016a98Nivolumab Small cell carcinoma of the lung61 (62)63 (57-68)10.07 (NR)NR3 (3)95 (97)
Antonia et al[8], 2016b61Nivolumab plus ipilimumab Small cell carcinoma of the lung35 (57)66 (58-71)12.03 (9.10-15.67)NR1 (2)57 (93)
Antonia et al[8], 2016c54Nivolumab plus ipilimumab Small cell carcinoma of the lung32 (59)61 (56-65)8.68 (8.27-9.6)NR048 (89)
Antonia et al[21], 2017476DurvalumabStage III non-small cell lung cancer334 (70.2)64 (NR)14.5 (0.2-29.9)120 (25.2)12 (2.5)433 (91)
Balar et al[22], 2017370Pembrolizumab plus cisplatinAdvanced, unresectable metastatic urothelial cancer286 (77)74 (34-94)5 (30-8.6)NRNRNR
Barlesi et al[23], 2018393AvelumabAdvanced non-small-cell lung cancer269 (68)64 (59-70)18.9 (IQR 13.2-23)102 (26)5 (1)324 (82)
Bott et al[24], 201821NivolumabResectable non–small cell lung cancer10 (48)67 (55-84)1.1 (0.57-1.13)NRNR18 (86)
Brohl et al[25], 201631Ipilimumab plus peginterferonUnresectable melanoma18 (58.1)65 (38-83)35.8 (19.7-50.2)NRNRNR
Cho et al[26], 201833PembrolizumabRelapsed thymic epithelial tumor21 (63.6)57 (26-78)14.9 (IQR 6.25-20.7)NRNRNR
Choueiri et al[3], 201855Avelumab plus axitinibAdvanced clear cell renal cell carcinoma42 (76)60 (55–68)13 (9.35-14.02)6 (11)3 (6)NR
Chung et al[27], 201911p53MVA vaccine combined with pembrolizumabAdvanced breast, pancreatic, hepatocellular, or head and neck cancer NRNR16.26 (15.42-17.27)NRNRNR
Dudnik et al[28], 2018260NivolumabNon-small cell lung cancer176 (68)67 (41-99)8.4 (2-16.8)NRNR197 (76)
Eggermont et al[29], 2015475IpilimumabHigh-risk stage III melanoma 296 (62)51 (20-84)7.5 (7-11.4)NRNRNR
Giaccone et al[30], 201840PembrolizumabThymic carcinoma28 (70)57 (25-80)8.4 (2-16.8)4 (10)2 (5)NR
Herbst et al[31], 202026Ramucirumab plus pembrolizumabAdvanced non-small-cell lung cancer21 (78)65 (56-72)33.3 (IQR 27.7-39.2)NR1 (4)26 (96)
Hodi et al[32], 2018313Nivolumab plus ipilimumabAdvanced melanomaNRNR20 (IQR 14-26)NRNRNR
Juergens et al[7], 2020136Durvalumab with or without tremelimumab and platinum-doubletLung cancer (unspecified)67 (49)61.9 (30.1-83.2)32.8 (IQR 28.1-33.6)8 (6)1 (1)NR
Loi et al[33], 201958Pembrolizumab plus trastuzumab Lung cancer (unspecified)052 (43-92)46.9 (48-NR)NRNRNR
Maio et al[34], 2017382TremelimumabMalignant mesothelioma283 (74)66 (60-72)19.61 (0.23-26.48)7 (2)3 (< 1%)NR
Mateos et al[35], 2019125Pembrolizumab plus pomalidomide and dexamethasoneMultiple myeloma77 (62)65 (60-72)25.7 (IQR 25.6-25.8)NRNRNR
Motzer et al[36], 2019550Nivolumab plus ipilimumabAdvanced renal cell carcinomaNRNR2 (1-3)NRNRNR
Sarocchi et al[37], 201859NivolumabAdvanced non-small cell lung cancer41 (NR)69 (44-81)8.1 (IQR 4.5-10.9)NRNR51 (86)
Scherpereel et al[6], 201963Nivolumab or nivolumab plus ipilimumabRelapsed malignant pleural mesothelioma47 (75)72.3 (32.5-87)32.4 (IQR 13.4-36.3)NRNR34 (54)
Tawbi et al[38], 201894Nivolumab plus ipilimumabMelanoma with brain metastases65 (69)59 (22-81)NRNRNRNR
Ueno et al[39], 2019a30Nivolumab alone Unresectable or recurrent biliary tract cancer NRNR20.1 (IQR 19.6-20.3)NRNRNR
Ueno et al[39], 2019b30Nivolumab in combination with cisplatin Unresectable or recurrent biliary tract cancerNRNR14 (6-NR)NRNRNR
Usmani et al[40], 2019a151Pembrolizumab Multiple myeloma70 (46)74 (70-79)5.1 (IQR 3.4-7)NRNRNR
Usmani et al[40], 2019b150LenalidomideMultiple myeloma71 (47)74 (70-788.2 (IQR 7-14)NRNRNR
Wrangle et al[41], 201821ALT-803, an IL-15 superagonist, in combination with nivolumabMetastatic non-small cell lung15 (71)55 (46-67)6.6 (IQR 3.4-9.6)NRNR12 (57)
Yang et al[42], 2018a42Preoperative chemotherapyNon-small cell lung cancer21 (50)NR6.6 (IQR 3.4-9.6)NR7 (17)NR
Yang et al[42], 2018b13IpilimumabNon-small cell lung cancer5 (38)NR6.9 (IQR 5.5-12.0)NR3 (23)NR